Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib

BACKGROUND: The T790M mutation of epithelial growth factor receptor (EGFR) is a major cause of the acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKIs) treatment for lung cancer patients. The Hippo pathway effector, TAZ, has emerged as a key player in organ growth and tumorigenesis, inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wei, Wei, Yunyan, Wu, Shuangshuang, Wang, Yun, Wang, Zhen, Sun, Yu, Cheng, Steven Y, Wu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429831/
https://www.ncbi.nlm.nih.gov/pubmed/25973173
http://dx.doi.org/10.1186/2045-3701-5-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429831/
https://www.ncbi.nlm.nih.gov/pubmed/25973173
http://dx.doi.org/10.1186/2045-3701-5-7

Ejemplares similares